OSI Pharmaceuticals Advances Diabetes Program; Glucokinase Activator Candidate PSN010 Advances to Phase I Clinical Trial
Latest Information Update: 16 Mar 2006
At a glance
- Drugs PSN 010 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 16 Mar 2006 New trial record.